Exact Sciences Corporation’s recent filing unveils that its Chief Financial Officer Elliott Jeffrey Thomas unloaded Company’s shares for reported $2.51 million on Aug 21. In the deal valued at $82.92 per share,30,210 shares were sold. As a result of this transaction, Elliott Jeffrey Thomas now holds 0 shares worth roughly $ 0.0.
Then, Baranick Brian sold 1,350 shares, generating $114,804 in total proceeds. Upon selling the shares at $85.04, the Gen. Mgr., Precision Oncology now owns 8,871 shares.
Before that, Doyle James Edward sold 2,000 shares. Exact Sciences Corporation shares valued at $194,840 were divested by the Director at a price of $97.42 per share. As a result of the transaction, Doyle James Edward now holds 52,110 shares, worth roughly $4.31 million.
The Benchmark Company downgraded its Exact Sciences Corporation [EXAS] rating to a Hold from a a Buy in a research note published on Tuesday.
Price Performance Review of EXAS
On Tuesday, Exact Sciences Corporation [NASDAQ:EXAS] saw its stock fall -2.89% to $82.70. On the same session, the stock had its day’s lowest price of $82.66, but rose to a high of $85.15. Over the last five days, the stock has gained 3.21%. Exact Sciences Corporation shares have risen nearly 67.04% since the year began. Nevertheless, the stocks have risen 128.20% over the past one year. While a 52-week high of $100.77 was reached on 07/19/23, a 52-week low of $29.27 was recorded on 01/06/23. SMA at 50 days reached $89.77, while 200 days put it at $71.37. A total of 1.01 million shares were traded, compared to the trading of 1.0 million shares in the previous session.
Levels Of Support And Resistance For EXAS Stock
The 24-hour chart illustrates a support level at 81.86, which if violated will result in even more drops to 81.01. On the upside, there is a resistance level at 84.35. A further resistance level may holdings at 85.99. The Relative Strength Index (RSI) on the 14-day chart is 44.29, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.07, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 50.08%. Stochastics %K at 66.41% indicates the stock is a holding.
How much short interest is there in Exact Sciences Corporation?
A steep rise in short interest was recorded in Exact Sciences Corporation stocks on Aug 14, 2023, dropping by -0.65 million shares to a total of 8.39 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 9.04 million shares. There was a decline of -7.75%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 4.69% of the overall stock float, the days-to-cover ratio (short ratio) fell to 5.3.
Exact Sciences Corporation [EXAS] – Who Are The Largest Shareholders?
In filings from The Vanguard Group, Inc., it is revealed that the company now owns 17,174,731 shares, or roughly 9.52% of the outstanding EXAS shares. In other words, the investor’s shares have risen by 163,744 from its previous 13-F filing of 17010987.0. Additionally, JPMorgan Investment Management, I increased 7.68% of its stake after which the total value it holdings stand at $1,200,425,853, while Wellington Management Co. LLP reduced -0.31% of its stake to hold $1.05 billion in the firm. Over the last quarter, BlackRock Fund Advisors purchased 481,268 shares of Exact Sciences Corporation, while ARK Investment Management LLC bought -4,224,089 shares. At present, Capital Research & Management Co is holding 6,797,960 shares valued at $663.07 million. Baillie Gifford & Co. owned 4,567,081 shares of the company at the time of its most recent 13F filing, worth $445.47 million.
According to FactSet, Exact Sciences Corporation’s share price will average $109.27 in the next year, based on opinions of analysts polled by the firm. This is up nearly 29.17 percent from its previous closing price of $85.16. Analysts expect Exact Sciences Corporation stock to reach the higher price of $130.00, while the lowest price estimate is $90.00. However, 22 analysts have rated EXAS stock as an Overweight in their predictions for 2023.